Raland Therapeutics Inc. was selected as a semi-finalist in the 43North Business competition. From almost 7,000 applicants, RTI was reviewed and was selected to be among the 113 top entries. RTI will now go to the next phase which is one step away from a top award of $1 million. Click here to read more
(BUFFALO, NY) Apr. 1, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in
(BUFFALO, NY) Feb. 15, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in
(CHARLESTON, S.C.) Mar 6, 2021/GlobeNewswire/ – Today, Efferent Labs announces an expanded development
Efferent Labs offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.
Efferent Labs® offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.
Sign up for email alerts of Press Releases and Efferent Labs’ breaking news
